Table 4.
Comparison among current series (excluding patients who progressed or died after CRT) and PACIFIC trial and PACIFIC-R.
| Current series | PACIFIC trial | PACIFIC-R | ||||
|---|---|---|---|---|---|---|
| CRT | CRT+durvalumab | Placebo | Durvalumab | Durvalumab | ||
| Time between end of RCT and start of durvalumab (days) | – | 47 | – | – | 56.0 | |
| Median FU (months) | 20.0 | 34.2 | 23.5 | |||
| OS | 1 year (%) | 62.8 | 82.5 | 74.6 | 83.1 | – |
| 2 years (%) | 62.8 | 69.4 | 55.3 | 66.3 | 71.2 | |
| Median (months) | 39 | 52 | 29.1 | 47.5 | NR | |
| PFS | 1 year (%) | 57.8 | 66.8 | 34.5 | 55.7 | 62.2 |
| 2 years (%) | 38.5 | 54.4 | 25.1 | 45 | 48.2 | |
| Median (months) | 16 | 26 | 5.6 | 16.9 | 21.7 | |
| Pneumonitis any grade | 18.8 | 30.7 | 24.8 | 33.9 | 17.9 | |
CRT, chemoradiotherapy; RCT, randomized clinical trial; FU, follow-up; OS, overall survival; PFS, progression-free survival.